Equity Ab Frankenius Buys 62,972 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) major shareholder Equity Ab Frankenius acquired 62,972 shares of the stock in a transaction dated Tuesday, December 17th. The shares were purchased at an average cost of $3.97 per share, with a total value of $249,998.84. Following the completion of the purchase, the insider now owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI opened at $4.05 on Friday. TriSalus Life Sciences, Inc. has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The company’s 50-day simple moving average is $4.14 and its 200-day simple moving average is $4.94. The stock has a market capitalization of $123.48 million, a P/E ratio of -1.63 and a beta of 0.56.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences in the second quarter valued at $240,000. Highbridge Capital Management LLC acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $1,184,000. Duquesne Family Office LLC lifted its holdings in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares in the last quarter. Walleye Capital LLC purchased a new position in TriSalus Life Sciences in the 3rd quarter valued at about $66,000. Finally, MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences in the third quarter worth approximately $184,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Roth Mkm initiated coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price objective on the stock. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Canaccord Genuity Group decreased their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Oppenheimer assumed coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, Northland Securities started coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, TriSalus Life Sciences currently has an average rating of “Buy” and a consensus target price of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.